Full Text Journal Articles in
Journal Bladder Cancer

Advertisement

Find full text journal articles






Revisiting an Old Conundrum: A Systematic Review and Meta-Analysis of Intravesical Therapy for Treatment of Urothelial Carcinoma of the Prostate.

Andrea Kokorovic, Mary E Westerman, Kate Krause, Mike Hernandez, Nathan Brooks, Colin P N Dinney, Ashish M Kamat, Neema Navai,

<h4>Background</h4>The optimal management of non-invasive (mucosal and/or ductal) urothelial carcinoma of the prostate remains elusive and there is a paucity of data to guide treatment.<h4>Objective</h4>Our objective was to systematically review and synthesize treatment responses to conservative management of non-invasive prostatic urothelial carcinoma using intravesical therapy.<h4>Methods</h4>A systematic literature search using MEDLINE, ... Read more >>

Bladder Cancer (Bladder cancer (Amsterdam, Netherlands))
[2021, 7(2):243-252]

Cited: 0 times

View full text PDF listing >>



Erratum: Outcomes of Trimodal Therapy for cT2-3 Urothelial Carcinoma in a Racially Diverse Population: A Single Institution Experience in the Bronx.

[This corrects the article DOI: 10.3233/BLC-200332.]. ... Read more >>

Bladder Cancer (Bladder cancer (Amsterdam, Netherlands))
[2021, 7(1):111-112]

Cited: 0 times

View full text PDF listing >>



Advertisement

Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer1

Bladder Cancer (Bladder cancer (Amsterdam, Netherlands))
[2020, 6(4):559-559]

Cited: 0 times

View full text PDF listing >>



Erratum to: Total Fluid Intake and the Risk of Recurrence in Patients with Non-Muscle Invasive Bladder Cancer: A Prospective Cohort Study.

Sylvia H J Jochems, Anke Wesselius, Maurice P Zeegers,

[This corrects the article DOI: 10.3233/BLC-180172.]. ... Read more >>

Bladder Cancer (Bladder cancer (Amsterdam, Netherlands))
[2020, 6(3):401]

Cited: 0 times

View full text PDF listing >>



The Urinary Microbiome and Bladder Cancer: Susceptibility and Immune Responsiveness.

Ciro Andolfi, Jeffrey C Bloodworth, Apostolos Papachristos, Randy F Sweis,

Bladder cancer is a highly prevalent disease worldwide and is associated with a high mortality rate. Across all stages of bladder cancer, immunotherapy has now become the cornerstone of treatment. The commensal microbiome has become a major focus of research given its impact on numerous states of human health and ... Read more >>

Bladder Cancer (Bladder cancer (Amsterdam, Netherlands))
[2020, 6(3):225-235]

Cited: 1 time

View full text PDF listing >>



Paper Alert

Edward M. Messing,

Bladder Cancer (Bladder cancer (Amsterdam, Netherlands))
[0, 2(2):283-284]

Cited: 0 times

View full text PDF listing >>



Paper Alert

Edward M. Messing,

Bladder Cancer (Bladder cancer (Amsterdam, Netherlands))
[0, 2(1):123-125]

Cited: 0 times

View full text PDF listing >>



Paper Alert

Edward M. Messing,

Bladder Cancer (Bladder cancer (Amsterdam, Netherlands))
[0, 1(2):185-187]

Cited: 0 times

View full text PDF listing >>



Non-Coding Mutations in Urothelial Bladder Cancer: Biological and Clinical Relevance and Potential Utility as Biomarkers.

Alexander Yang, Christopher N Cross, Jeffrey P Townsend,

Bladder Cancer (Bladder cancer (Amsterdam, Netherlands))
[2020, 6(2):211-213]

Cited: 1 time

View full text PDF listing >>



Review of SWOG S1314: Lessons from a Randomized Phase II Study of Co-Expression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer.

Peter Boxley, Melissa Plets, Thomas W Flaig,

SWOG1314 is a randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer. COXEN is a biomarker approach in which predictive biomarkers are developed using <i>in vitro</i> data, which may then be applied directly into a clinical testing application. Two separate Gene Expression Models ... Read more >>

Bladder Cancer (Bladder cancer (Amsterdam, Netherlands))
[2020, 6(2):123-129]

Cited: 2 times

View full text PDF listing >>



Plasmacytoid urothelial carcinoma: response to chemotherapy and oncologic outcomes.

Leonidas N Diamantopoulos, Ali Raza Khaki, Petros Grivas, John L Gore, George R Schade, Andrew C Hsieh, John K Lee, Todd Yezefski, Evan Y Yu, Michael T Schweizer, Heather H Cheng, Sarah P Psutka, Daniel W Lin, Maria S Tretiakova, Funda Vakar-Lopez, Robert B Montgomery, Jonathan L Wright,

<h4>Background</h4>Plasmacytoid urothelial carcinoma is a rare bladder cancer variant with scarce data on outcomes and prognostic factors.<h4>Objective</h4>We report our institutional experience with this histology to determine response to neoadjuvant chemotherapy, definitive surgery and survival.<h4>Methods</h4>We conducted a retrospective chart review of consecutive patients with plasmacytoid, as well as conventional urothelial carcinoma ... Read more >>

Bladder Cancer (Bladder cancer (Amsterdam, Netherlands))
[2020, 6(1):71-81]

Cited: 0 times

View full text PDF listing >>



Lifestyle and Non-muscle Invasive Bladder Cancer Recurrence, Progression, and Mortality: Available Research and Future Directions.

Kyle B Zuniga, Rebecca E Graff, David B Feiger, Maxwell V Meng, Sima P Porten, Stacey A Kenfield,

<h4>Background</h4>A broad, comprehensive review of studies exploring associations between lifestyle factors and non-muscle invasive bladder cancer (NMIBC) outcomes is warranted to consolidate recommendations and identify gaps in research.<h4>Objective</h4>To summarize the literature on associations between lifestyle factors and clinical outcomes among patients with NMIBC.<h4>Methods</h4>PubMed was systematically queried for articles published through ... Read more >>

Bladder Cancer (Bladder cancer (Amsterdam, Netherlands))
[2020, 6(1):9-23]

Cited: 0 times

View full text PDF listing >>



PD-L1/PD-1 Biomarker for Metastatic Urothelial Cancer that Progress Post-platinum Therapy: A Systematic Review and Meta-analysis.

Wei Phin Tan, Wei Shen Tan, Brant A Inman,

<h4>Background</h4>Immune checkpoint inhibitors (ICI) are extremely expensive and most patients with metastatic urothelial carcinoma (mUC) do not benefit significantly from their use.<h4>Objective</h4>We performed a systematic review and meta-analysis to determine response rates and survival outcomes on patients with mUC progressing despite prior platinum-based chemotherapy receiving ICI stratified by biomarker status.<h4>Methods</h4>We ... Read more >>

Bladder Cancer (Bladder cancer (Amsterdam, Netherlands))
[2019, 5(3):211-223]

Cited: 3 times

View full text PDF listing >>



Evaluation of Hematuria in a Large Public Health Care System.

Rashed Ghandour, Yuval Freifeld, Nirmish Singla, Yair Lotan,

Background:Hematuria is the most common presenting symptom in bladder cancer, but many patients are not adequately evaluated. Objectives:To evaluate the type and frequency of hematuria evaluation in a large public health care system. Patients and Methods:Electronic medical records of adult patients with urinalysis positive for hematuria (≥3 RBCs/HPF) from January ... Read more >>

Bladder Cancer (Bladder cancer (Amsterdam, Netherlands))
[2019, 5(2):119-129]

Cited: 0 times

View full text PDF listing >>



Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer.

Megan M Tu, Terry L Ng, Florus C De Jong, Tahlita C M Zuiverloon, Francesco G T Fazzari, Dan Theodorescu,

<h4>Background</h4>The activity of PD-1/PD-L1 inhibitors in the treatment of advanced bladder cancer (BC) is promising for many patients. However, a subset of patients do not benefit from treatment, thus leading to an effort to better identify predictive molecular biomarkers of response.<h4>Objective</h4>To conduct a systematic review of the literature on predictive ... Read more >>

Bladder Cancer (Bladder cancer (Amsterdam, Netherlands))
[2019, 5(2):131-145]

Cited: 3 times

View full text PDF listing >>



Recovering from Cystectomy: Patient Perspectives.

Carmit K McMullen, Marilyn L Kwan, Janice C Colwell, Julie R Munneke, James V Davis, Alison Firemark, Neon Brooks, Marcia Grant, Scott M Gilbert, Andrea Altschuler,

<h4>Background</h4>Bladder cancer patients who undergo cystectomy and urinary diversion face functional and quality-of-life challenges. Little is known about these patients' experiences during decision-making, surgery, and recovery, or how they vary by treatment setting.<h4>Objective</h4>To learn about patients' experiences with treatment choice, surgical care, and recovery across health settings. Understanding patient experiences ... Read more >>

Bladder Cancer (Bladder cancer (Amsterdam, Netherlands))
[2019, 5(1):51-61]

Cited: 2 times

View full text PDF listing >>



The Outcome of Post-Chemotherapy Retroperitoneal Lymph Node Dissection in Patients with Metastatic Bladder Cancer in the Retroperitoneum.

Nick W Liu, Katie S Murray, S Machele Donat, Harry W Herr, Bernard H Bochner, Guido Dalbagni,

<h4>Purpose</h4>While a definitive cure can be achieved by radical cystectomy and pelvic lymph node dissection in select patients with regional lymphadenopathy, the benefit remains uncertain in patients who present with non-regional metastases. We analyzed the survival outcomes of post-chemotherapy retroperitoneal lymph node dissection.<h4>Materials and methods</h4>We reviewed our institutional database and ... Read more >>

Bladder Cancer (Bladder cancer (Amsterdam, Netherlands))
[2019, 5(1):13-19]

Cited: 0 times

View full text PDF listing >>



Immune Checkpoint B7x (B7-H4/B7S1/VTCN1) is Over Expressed in Spontaneous Canine Bladder Cancer: The First Report and its Implications in a Preclinical Model.

Damini Chand, Deepika Dhawan, Alexander Sankin, Xiaoxin Ren, Juan Lin, Mark Schoenberg, Deborah W Knapp, Xingxing Zang,

<h4>Background</h4>B7x (B7-H4/B7S1/VTCN1), an inhibitory immune checkpoint molecule is a potential therapeutic target owing to its immunosuppressive effect and well-known expression in cancers. Immune checkpoints in canine bladder cancer are largely undefined. Here, we report the first evaluation on expression of B7x in spontaneous canine invasive bladder cancer, a novel model ... Read more >>

Bladder Cancer (Bladder cancer (Amsterdam, Netherlands))
[2019, 5(1):63-71]

Cited: 2 times

View full text PDF listing >>



Clinical Trials Corner.

Piyush K Agarwal, Cora N Sternberg,

Bladder Cancer (Bladder cancer (Amsterdam, Netherlands))
[2018, 4(4):447-449]

Cited: 0 times

View full text PDF listing >>



Changes in Lean Muscle Mass Associated with Neoadjuvant Platinum-Based Chemotherapy in Patients with Muscle Invasive Bladder Cancer.

Kalen J Rimar, Alexander P Glaser, Shilajit Kundu, Edward M Schaeffer, Joshua Meeks, Sarah P Psutka,

<h4>Background</h4>Baseline sarcopenia or severe lean muscle deficiency is independently associated with increased mortality after cystectomy for muscle-invasive urothelial carcinoma of the bladder (MIUC). The impact of chemotherapy on muscle mass in MIUC patients remains undefined.<h4>Objectives</h4>To describe preoperative changes in body composition in MIUC patients receiving platinum-based neoadjuvant chemotherapy (NC).<h4>Methods</h4>Patients with ... Read more >>

Bladder Cancer (Bladder cancer (Amsterdam, Netherlands))
[2018, 4(4):411-418]

Cited: 3 times

View full text PDF listing >>



Intravesical Radiofrequency-Induced Chemohyperthermia for Carcinoma in Situ of the Urinary Bladder: A Retrospective Multicentre Study.

F Johannes P van Valenberg, Amir Kajtazovic, Giorgio Canepa, Gerson Lüdecke, Jill-Isabel Kilb, Katja K H Aben, Ofer Nativ, Sanjeev Madaan, Benjamin Ayres, Rami Issa, J Alfred Witjes,

<h4>Objective</h4>To examine the effect of intravesical radiofrequency-induced chemohyperthermia (RF-CHT) in carcinoma <i>in-situ</i> (CIS) patients overall and split according to previously received therapy.<h4>Methods</h4>CIS patients that underwent an induction and maintenance phase of≥6 RF-CHT instillations, and had either pathology or cystoscopy plus cytology available at 6 months of follow-up were retrospectively included. ... Read more >>

Bladder Cancer (Bladder cancer (Amsterdam, Netherlands))
[2018, 4(4):365-376]

Cited: 1 time

View full text PDF listing >>



Challenging Cases in Urothelial Cancer.

Mark S Soloway,

Bladder Cancer (Bladder cancer (Amsterdam, Netherlands))
[2018, 4(4):441-444]

Cited: 0 times

View full text PDF listing >>



Evaluation of Intraoperative Versus Postoperative Adjuvant Mitomycin C with Nephroureterectomy for Urothelial Carcinoma of the Upper Urinary Tract.

Blake Noennig, Shahab Bozorgmehri, Russell Terry, Brandon Otto, Li-Ming Su, Paul L Crispen,

<h4>Background</h4>Results of randomized trials support a single dose of intravesical chemotherapy following radical nephroureterectomy (RNU) for urothelial carcinoma.<h4>Objective</h4>To evaluate the impact of the timing of intravesical mitomycin C (MMC) administration on the rate of bladder tumor recurrence (BTR) following RNU.<h4>Methods</h4>We performed a retrospective review of patients who underwent RNU for ... Read more >>

Bladder Cancer (Bladder cancer (Amsterdam, Netherlands))
[2018, 4(4):389-394]

Cited: 1 time

View full text PDF listing >>



Perioperative Blood Transfusions and Bladder Cancer Outcomes.

Edward M Messing,

Bladder Cancer (Bladder cancer (Amsterdam, Netherlands))
[2018, 4(4):445-446]

Cited: 0 times

View full text PDF listing >>



Increased Surgical Complications in Smokers Undergoing Radical Cystectomy.

Niranjan J Sathianathen, Christopher J Weight, Stephanie L Jarosek, Badrinath R Konety,

<h4>Background</h4>Not only is smoking a risk factor for the development of bladder cancer, it has also been implicated in increasing surgical morbidity and mortality. In general, the demographic and clinical characteristics of smokers are different to non-smokers which can bias the results of the impact of smoking.<h4>Objective</h4>To evaluate the impact ... Read more >>

Bladder Cancer (Bladder cancer (Amsterdam, Netherlands))
[2018, 4(4):403-409]

Cited: 2 times

View full text PDF listing >>



Advertisement


Disclaimer

0.9077 s